Clinical Trial Update: A Phase 1 Study of SYNCAR-001 + STK-009 Without Conditioning Chemotherapy (Lymphodepletion) in Subjects With Severe, Refractory Systemic Autoimmune Rheumatic Disease [Phase 1]

View source ↗

Summary

Synthekine reports a Phase 1 study of SYNCAR-001 plus STK-009 without lymphodepletion in subjects with severe, refractory systemic autoimmune rheumatic diseases…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lupus Nephritis
• Systemic Lupus Erythematosus
• Systemic Sclerosis

Drugs mentioned

• STK-009 (Orthogonal interleukin-2 (IL-2) variant)
• SYNCAR-001

Snippet

Sponsor: Synthekine | Conditions: Systemic Lupus Erythematosus, Lupus Nephritis | Phase 1 | Status: ACTIVE_NOT_RECRUITING